PYXIS ONCOLOGY INC (PYXS)

PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024

PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024

PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice...

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference

BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics...

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation...

3 Biotech Stocks to Buy on the Dip: March 2024

Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three...

PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pyxis Oncology (NASDAQ:PYXS) just reported results for the fourth quarter of 20...

PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023

PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share the fourth quarter of 2023.

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected...

From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires

These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning!

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation...

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation...

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models The...

Pyxis Oncology Announces $50 Million Private Placement

3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024

With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.

Friday Sector Leaders: Semiconductors, Drugs

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation...

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer

Dr. Kobayashi brings over 25 years of experience in oncology drug development, including Antibody Drug Conjugates (ADCs) and other oncology modalities

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with...

Inspiring the Next Generation of Entrepreneurs at the Diversity and Equity Accelerator through Learning for Startups (DEALS) Workshop

/PRNewswire/ -- In order to cultivate a more inclusive and dynamic landscape for engineering and STEM startups, Black Women in Science and Engineering (BWISE)...

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...